Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 55Active not recruiting 29Not yet recruiting 16Completed 16Terminated 4Suspended 2Withdrawn 1Unknown 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 3Thoracic 2Gastrointestinal 1

Conditions

Breast Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Interventional × trastuzumab deruxtecan × Clear all
NCT05744375 2026-04-02

TRANSCENDER

Spanish Breast Cancer Research Group

Phase 2 Terminated
2 enrolled 10 charts
Breast

Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Daiichi Sankyo

Phase 2 Terminated
253 enrolled 21 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03505710 2025-05-30

DESTINY-Lung01

Daiichi Sankyo

Phase 2 Terminated
181 enrolled 17 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Silverback Therapeutics

Phase 1/2 Terminated
2 enrolled 9 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡